Open AccessSwitching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
Author(s) -
Walid Ibrahim,
Zeiad H Eldaly,
Mohamed G. A. Saleh,
Mahmoud Rateb,
Ahmed H. Aldoghaimy
Publication year - 2019
Publication title -
korean journal of ophthalmology/korean journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.357
H-Index - 30
eISSN - 2092-9382
pISSN - 1011-8942
DOI - 10.3341/kjo.2018.0037
Subject(s) - aflibercept , medicine , visual acuity , ophthalmology , ranibizumab , retinal , macular edema , diabetic macular edema , diabetic retinopathy , diabetes mellitus , surgery , bevacizumab , chemotherapy , endocrinology
To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections.